Estrella Immunopharma, Inc. (NASDAQ:ESLA) Financings
Financings
| Raise | Date |
|---|---|
| Registered direct offering of common stock and pre-funded warrants with concurrent private placement common warrants Closed: US$8M raised · US$1.58 a share · Warrants at US$1.39 for 60 months · Aegis Capital Corp. Dealers: Aegis Capital Corp. (lead) Use of proceeds: General corporate purposes and working capital | Jan 6, 2026 |
| Private placement of shares of common stock Announced: about US$3.35M · US$1.5 a share Use of proceeds: Complete Phase I of the STARLIGHT-1 trial of EB103 in adults with relapsed/refractory B-cell non-Hodgkin's lymphoma | Jun 3, 2025 |